You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Novel Product Recently Approved by the FDA for Treatment of Acute Migraine and Cluster Headache SAN DIEGO, CA, and DEERFIELD, IL (August 3, 2009): Zogenix, Inc. (“Zogenix”), a privately held...
MELVILLE, N.Y., Aug 01, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) today announced further results from the Phase III SATURN study showing that Tarceva(R) (erlotinib)...
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jul 13, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
MELVILLE, N.Y., Jun 15, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
Follow U.S. news
